The 8th Hematology Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Jian Hou from Renji Hospital of Shanghai JiaoTong University School of Medicine, to share insights on the current status, challenges, and future treatment modes of multiple myeloma (MM).

Mantle cell lymphoma (MCL) is an aggressive lymphoma with high malignancy and poor treatment outcomes, especially for elderly patients or those in poor health. Optimizing treatment regimens for these patient groups is crucial. At the recent 29th European Hematology Association (EHA) annual meeting, Dr. Michael Wang from University of Texas MD Anderson, Houston, USA presented the latest results from the phase 3, double-blind, placebo-controlled ECHO trial (LB3439), which evaluated the efficacy of acalabrutinib combined with bendamustine and rituximab in treatment-naïve MCL patients. "Oncology Frontier - Hematology Frontier" interviewed Professor Wang to interpret these groundbreaking findings.

The 29th European Hematology Association (EHA) Annual Meeting was successfully held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it annually attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's conference, several studies from Dr. He Huang's team at The First Affiliated Hospital, Zhejiang University School of Medicine were selected for poster presentations. These studies, covering both basic and clinical research, provide new perspectives and theoretical foundations for the treatment of hematological diseases. This article introduces five of these studies, including the impact of telomere length on transplant prognosis, the role of lactate in acute graft-versus-host disease, the regulatory mechanisms of hematopoietic endothelial cell (HECs) generation, breakthroughs in CD7 CAR-T therapy for T-cell malignancies, and the prospects of XPO1 inhibitors in the treatment of Burkitt lymphoma.

The European Hematology Association (EHA) annual meeting, one of the most influential international academic conferences in the field of hematology, gathers numerous experts and scholars worldwide every year. The aim is to share and deeply discuss innovative ideas and the latest scientific and clinical research advancements in hematology, thereby promoting continuous progress in the field. This year’s conference unveiled the latest results from studies on the use of the erythroid maturation agent luspatercept in the treatment of lower-risk myelodysplastic syndromes (LR-MDS), demonstrating promising therapeutic potential. Oncology Frontier - Hematology Frontier invited Dr. Chungkang Chang , Director of the Hematology Department at Shanghai Sixth People’s Hospital Affiliated to Shanghai JiaoTong University and Deputy Director of the Shanghai Blood Research Institute, to provide an in-depth analysis of the field's current status and research content, aiming to offer valuable references for clinical practice.